Companies / IXC

INVEX THERAPEUTICS LTD

ASX:IXCPharmaceuticals, Biotechnology & Life Sciences
75.2M shares on issueASX (delayed) · as of 28 July 2026$0.13price · delayed$9.0Mmarket cap · indicative
A
Dilution grade

Runway 4–8 quarters

Cash runway7.7 quarters of funding
Share-count growth (24m)0.0%no issuance filings since 2024
Raise cadence (24m)0 cash raises
Options & rights overhang0.0% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

INVEX THERAPEUTICS LTD has no share-issuance (Appendix 2A) filings on record in the window, and the company states it has lodged no new share-issuance (Appendix 2A) filings since January 2024. There were no capital raises in the 24-month window. At the June 2026 quarter the company reported A$3.9M in cash, equal to 7.7 quarters of cover at its recent spending rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
0.0%
Max option dilution
0.0%
ITM option dilution
0
Raises · last 12 months
7.7 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 75.2M per ASX (delayed) (28 July 2026).
74.9M75.2M75.5MDec 24Sept 25July 26

Cash runway

7.7 qtrs
More than four quarters of funding at the recent spend rate.
$3.9M available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 2 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
26 June 20243H · cancellationIXC : ORDINARY FULLY PAID75.2MAppendix 3H
8 Apr 20243H · cancellationIXC : ORDINARY FULLY PAID75.2MAppendix 3H
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

No equity raises in the last 24 months.
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

No options or rights over unissued shares on record.

Director dealings

No director dealing notices (Appendix 3Y) on record.
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

23 July 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
24 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
23 Apr 2026Invex to Expand Preclinical Research Program
23 Mar 2026Resignation of Joint Company Secretary
17 Feb 2026Results of Meeting
12 Feb 2026$PAppendix 4D and Half Year Report
22 Jan 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
16 Jan 2026Notice of Annual General Meeting/Proxy Form
20 Nov 2025Deferral of Annual General Meeting
10 Nov 2025Initial Director's Interest Notice x 2
9 Nov 2025$PReinstatement to Quotation
9 Nov 2025$PBoard and Officer Appointments and Company Address Change
7 Nov 2025Final Director's Interest Notice
7 Nov 2025Final Director's Interest Notice
7 Nov 2025Resignation of Directors, Co Sec and Cancellation of Meeting
7 Nov 2025$PSuspension from Official Quotation
7 Nov 2025$PPause in Trading
3 Nov 2025Exenatide shows additional positive benefits in brain model
24 Oct 2025Notice of Annual General Meeting/Proxy Form
17 Oct 2025Change in substantial holding

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.